EPIGENETIC ALTERATIONS IN MYELOID MALIGNANCIES: LINKING CHROMATIN REMODELING TO DISEASE PROGRESSION
Universal Journal of Pharmaceutical Research · 15.07.2026
DOI: 10.22270/ujpr.v11i3.1579 ↗Kurz gefasst
Fachartikel in der Zeitschrift Universal Journal of Pharmaceutical Research, online erschienen am 15.07.2026. Verfasst von Emmanuel Ifeanyi Obeagu und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Myeloid cancers, such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs), develop from the clonal alteration of hematopoietic stem and progenitor cells. Apart from genetic mutations, epigenetic dysregulation has become a key factor in disease onset, advancement, and resistance to treatment. Anomalies in DNA methylation, histone changes, and chromatin rearrangement interfere with normal blood cell differentiation, promote clonal growth, and create diverse malignant cell populations. Alterations in essential epigenetic regulators like DNMT3A, TET2, IDH1/2, ASXL1, and EZH2-collaborate with oncogenic alterations to facilitate leukemogenesis and resistance to treatment. These epigenetic changes act as prognostic indicators and offer targetable weaknesses, such as DNA methyltransferase inhibitors, histone deacetylase inhibitors, and therapies aimed at mutant IDH or EZH2. This review compiles existing information on the epigenetic features of myeloid tumors, emphasizing its importance in disease advancement and treatment strategies. Peer Review History: Received 3 April 2026; Reviewed 12 May 2026; Accepted 7 June; Available online 15 July 2026 Academic Editor: Dr. Tamer Elhabibi, Suez Canal University, Egypt, tamer_hassan@pharm.suez.edu.eg Reviewers: Dr. Fátima Morales Marín, University of Murcia, Spain, fatima.morales@um.es Dr. Francis Adou Yapo, Felix Houphouet Boigny, University of Abidjan, Ivory Coast, fyapo@yahoo.fr
Zitieren
APA
Obeagu, E. I., & Musimwa, I. (2026). EPIGENETIC ALTERATIONS IN MYELOID MALIGNANCIES: LINKING CHROMATIN REMODELING TO DISEASE PROGRESSION. Universal Journal of Pharmaceutical Research. https://doi.org/10.22270/ujpr.v11i3.1579
Vancouver
Obeagu EI, Musimwa I. EPIGENETIC ALTERATIONS IN MYELOID MALIGNANCIES: LINKING CHROMATIN REMODELING TO DISEASE PROGRESSION. Universal Journal of Pharmaceutical Research. 2026. doi:10.22270/ujpr.v11i3.1579
BibTeX
@article{Obeagu2026,
author = {Obeagu, Emmanuel Ifeanyi and Musimwa, Idi},
title = {EPIGENETIC ALTERATIONS IN MYELOID MALIGNANCIES: LINKING CHROMATIN REMODELING TO DISEASE PROGRESSION},
journal = {Universal Journal of Pharmaceutical Research},
year = {2026},
doi = {10.22270/ujpr.v11i3.1579}
}
EUVIMED